Quantitation of the CNS phenotypes induced by AcGq3
| Genotype | Stalling phenotype | Midline crossover | % Midline crossover |
|---|---|---|---|
| C155-GAL4/UAS-AcGq3 | 106/308* (34.41%) | 64/1331-160 | 48.10 |
| UAS-AcGq3; +/+; ftzng-GAL4 | 171/854* (20.02%) | 86/4271-160 | 20.14 |
| UAS-AcGq3; robo1/+; ftzng-GAL4, UAS-tauβgal | 316/6231-160 (5.35)1-213 | 50.7 | |
| robo1/+ | 12/2451-160 (2.10)1-213 | 4.8 | |
| C155-GAL4/+; UAS-AcGq3/+; UAS-roboY-F/+ | 0/1611-160 | 0.0 | |
| C155-GAL4/UAS-AcGq3;fra/CyoActβgal | 37/2591-160 | 15.3 | |
| C155-GAL4/UAS-AcGq3;fra3/fra4;+/+ | 13/2451-160 | 5.3 |
↵* indicates total number of hemisegments used to quantitate the stalling phenotype observed in embryos of stage 14–16.
↵F1-160 indicates the total number of abdominal segments used to quantitate midline crossing.
↵F1-213 denotes expressivity, which is calculated as the ratio of the total number of midline crossovers observed and the total number of embryos showing at least one crossover.